tradmap

VYGR Voyager Therapeutics, Inc.

$3.37 -4.94%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Voyager Therapeutics, Inc. (VYGR) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $207 million. Shares last traded at $3.37, 39.3% below their 52-week high. Over the past year the stock is down 8.8%. Net profit margin is -312.6%, below the peer median of 5.3%. Revenue declined 49.5% year over year.

Market Cap
$207M
Shares Out
61.6M
EPS (TTM)
$-4.01
P/E Ratio
P/S Ratio
6.02
P/B Ratio
1.34
Dividend / Share
Dividend Yield
52-Week High
$5.54
52-Week Low
$2.94
Volume
64,965
Avg Vol (3m)
41,875.667

Performance

1W
-2.46%
1M
+9.25%
3M
-7.04%
6M
-14.49%
YTD
-16.60%
1Y
-8.81%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
50.61
SMA (50)
$3.32
SMA (200)
$3.78
Price vs SMA50
+1.49%
Price vs SMA200
-10.97%
ATR (14)
$0.16

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$34M
Net Income
$-108M
Gross Margin
Operating Margin
-340.1%
Net Margin
-312.6%
Return on Equity
-69.8%
Return on Assets
-54.5%
Current Ratio
7.51
Debt / Equity
0.28
Revenue Growth (YoY)
-49.5%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-0.87 2026-08-06
Q1 2026 $-0.47 2026-05-07
FY 2025 $-2.04 2026-03-09
Q3 2025 $-1.57 2025-11-10
Q2 2026 $-1.10 2026-08-06
Q1 2026 $-0.53 2026-05-07

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

VYGR vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
6.02 / 19.49 med
-69% discount
Net margin vs peers
-312.6% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.